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length of stay in the hospital is about 3.5 days. CONCLUSIONS: After the logistic and
linear regressions, the results showed a small correlation with cellulitis. The likelihood 
of having a bacterial infection or having infections with microorganisms increases with 
cellulitis. The likelihood of having a venous catheterization, having the skin drained,
or having the tendon sheath of the hand explored increases with cellulitis.
INFECTION – Cost Studies
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THE ECONOMIC IMPACT OF TRANSITIONING VALACYCLOVIR TO OVER
THE COUNTER STATUS FOR THE TREATMENT OF GENITAL HERPES
Chang JY, Nichol MB
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OBJECTIVES: Genital herpes affects more than 45 million individuals in the United 
States with an estimated 400,000 physician ofﬁ ce visits each year for primary infec-
tions. With no cure for the herpes infection, it can be transmitted from the infected 
individuals to the unsuspecting population throughout the lifetime of the infected.
With the approaching patent expiration for the prescription drug valacyclovir 
(Valtrex) in 2009, this study examines the implications of transitioning valacyclovir 
to an over the counter (OTC) status. METHODS: A decision analysis model was used
to examine the current prescription based requirement for valacyclovir compared to 
the OTC status for the product. The analysis was constructed from a societal perspec-
tive using a budget impact model. A simulation model conducted in a hypothetical 
cohort of 10,000 individuals with primary genital herpes in the United States with 
direct medical cost as the principal outcome. Cost estimations are based on literature 
review and national health care databases. A sensitivity analysis through a Monte 
Carlo simulation will assess the validity of the cost estimates. RESULTS: The transition 
of valacyclovir to OTC status will amount to an average annual savings of $707 
($544–$868) per newly infected individual in the form of direct medical expenditures. 
The annual average cost for the OTC transition is $108 per newly infected, compared
to the annual average cost of the prescription based requirement of $815 per newly
infected. Aggregate annual savings to the United States from newly infected individuals 
is $282 million per year. CONCLUSIONS: Transitioning valacyclovir to OTC status 
is a cost saving measure for society, largely due to the decrease in physician ofﬁ ce visits 
for valacyclovir prescriptions. Further studies will need to address speciﬁ c population 
needs in regards to herpes education, feasibility of self-diagnosis, viral resistance and
indirect cost.
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OBJECTIVES: Studies in Mexico have shown that the health expenditure attributed
to antirretroviral treatments for naïve and experimented patients is high. This has an 
impact on the national budget of the public health institutions, especially for units
from the Ministry of Health which deal with the largest number of HIV/AIDS cases
in the country. The objective of this analysis was to estimate the ﬁ nancial impact of 
increasing the availability of atazanavir for the treatment of patients with HIV/AIDS 
in the MoH institutions. METHODS: A budgetary impact model based on epidemio-
logical data, treatment costs and market uptake for four proteasa inhibitors (PI) in a 
time horizon of ﬁ ve years was developed. A baseline scenario, where the current 
PIs market distribution remains the same, was compared with a scenario where 
atazanavir availability is increased. RESULTS: The estimated numbers of infected
HIV/AIDS subjects will grow around 53.48% in the next ﬁ ve years. As a result,
more resources will be needed to face the increasing burden of the disease. The com-
parisons between the two scenarios show that the estimated budget impact related to 
the acquisition of PI is cost-saving. The estimated savings in 2009 are of US$1.168 
million increasing 3.4 times during the ﬁ ve years period. Savings from the treatment 
of main side effects such as, diarrhea and cholesterol lowering intervention are also
observed (US$ 12,777 and US$17,861 in 2009 respectively). CONCLUSIONS: An 
increase in the utilization of atazanavir represents a good clinical and economic option
for the Mexican MoH in the short and long run. The highest impact in the budget
is produced mainly by the pharmacological costs. However, budget savings are also 
derived from the reduction of treatment costs side effects such as diarrhea and
hypercholesterolemia.
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OBJECTIVES: To quantify the Budget Impact of antimalaria drug formulary decisions
in a Nigerian Teaching Hospital. METHODS: A retrospective random sample of 
17,000 prescriptions (2001–2008) with the wholesale prices of each prescribed drug 
was collected from pharmacy records. The total number of prescriptions per day, the
date and the therapeutic class of the prescribed drugs were also noted. From this data,
estimates of the proportion of patients that received a particular antimalaria medicine 
and the year of introduction or deletion of the drug from the drug formulary were
made. The costs of a complete dose required for the treatment of a patient suffering
from malaria when prescribed a given antimalaria drug were calculated from the 
extracted wholesale prices. These variables served as input in a stochastic Monte Carlo
model which was built to simulate the Budget Impact of each identiﬁ ed formulary 
decision by subtracting the total cost of drugs in the Old Drug Scenario from that of 
the New Drug Scenario. Negative values represent cost savings. A sensitivity analysis 
was conducted by varying the input parameters by o 50%. RESULTS: Halofantrine 
was introduced into the hospital formulary in 2002 with a resultant signiﬁ cant (p 
0.0001) savings of NGN1.02million with a mean of NGN0.16million. The introduc-
tion of arthemisinin combination therapies (ACTs) in 2005 with the addition of IM 
arthemether in 2007 led to an increase expenditure of NGN3.02million (p  0.0001) 
and NGN0.07million (p  0.171) respectively. In 2008, the number of patients that 
were prescribed ACTs decreased from 80.9% in 2007 to 67.9%. This strategy pro-
duced a cost saving of NGN6.27million which was signiﬁ cant (p  0.0001). Sensitivity 
analysis conﬁ rmed the robustness of the model. CONCLUSIONS: Introduction of 
ACTs into the hospital drug formulary signiﬁ cantly increased drug expenditure. We 
therefore suggest that a CEA of available antimalarials may prove to be a valuable 
tool to this budget holder.
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OBJECTIVES: Previous economic analyses of MRSA-conﬁ rmed cSSTI have not 
included costs related to outpatient parenteral antibiotic therapy (OPAT). The objec-
tive of this analysis was to develop an economic model to estimate medical and 
drug costs within both inpatient and outpatient components of care for treating
MRSA cSSTI. METHODS: A 4-week decision model was developed to estimate the 
direct total, inpatient, and outpatient costs of treating MRSA cSSTI from a U.S. payer 
perspective taking into account successes, failures, and adverse events (AEs). Com-
parators included vancomycin, linezolid, daptomycin, and tigecycline. Published 
literature and database analyses, with validation by experts, provided clinical inputs
and resource use data including MRSA efﬁ cacy, length of stay (LOS), consequences 
of AEs and cSSTI failure, OPAT services, among others. Cost data was derived
from literature and standard CPT coding reimbursements. The base case analysis 
assumed equal efﬁ cacy and equal LOS of 4 days among comparators. Univariate and 
probabilistic sensitivity analyses tested efﬁ cacy, complication rates, LOS, and other
resource use parameters. Costs were reported in 2008US$. RESULTS: Total drug 
acquisition costs were 4–6 times lower for vancomycin compared to tigecycline, 
linezolid, and daptomycin. However, the total 4-week cost of treatment including 
drugs, clinical failures, complications, and OPAT were lowest for linezolid ($8,149), 
followed by vancomycin ($8,974), tigecycline ($10,333), and daptomycin ($11,362). 
Oral linezolid reduced the outpatient medical costs by 10-fold versus IV comparators.
The most sensitive model variables for total cost were the MRSA efﬁ cacy, hospital
LOS, OPAT days, and line placement/complication costs. CONCLUSIONS: Although 
total drug acquisition costs were lower for vancomycin vs. comparators, the model
suggests linezolid provides total cost savings in cSSTI versus IV therapies, particularly
in the outpatient arena. The budget impact of antimicrobials for cSSTI should consider
total medical cost offsets from both inpatient and outpatient perspectives.
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OBJECTIVES: To evaluate the cost-effectiveness of daptomycin versus vancomycin in
complicated skin and soft structure infections (cSSSI). METHODS: A decision analytic 
(DA) model was developed to evaluate the cost-effectiveness of daptomycin versus
vancomycin in cSSSI. The payer perspective was adopted and total direct costs related
to cSSSI were measured. Efﬁ cacy (cure) was deﬁ ned as a patient who was treated
empirically with the study drug, had a positive culture of Methicillin-resistant Staphy-
lococcus aureus did not relapse at the test of cure. Previous literature was used to 
determine the parameters of the model. Costs were determined from 2008 Drug Red 
Book and Decision Support System database. Primary outcome was the incremental
cost-effectiveness ratio (ICER) of daptomycin over vancomycin. One-way sensitivity
analyses was performed for all parameters and presented in a tornado diagram. 
Probabilistic sensitivity analysis was performed on all parameters using 10,000 trial
simulations. RESULTS: In the base-case analysis, daptomycin and vancomycin arms 
had total direct costs of $11,162.88 and $16,307.74, respectively. Cure probabilities
for patients in the daptomycin and vancomycin arms were 51.6% and 40.2%, respec-
tively. Cost-effectiveness ratio for daptomycin and vancomycin were $21,619.78/cure 
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and 40,573.33/cure, respectively. ICER was -$44,974.88/cure favoring daptomycin.
Results from the one-way sensitivity analysis showed that duration of vancomycin 
intravenous treatment, cost of hospital night stay, and duration of daptomycin intra-
venous treatment were inﬂ uential on the ICER; however, no break-even points were 
established and the model remained robust. Probabilistic sensitivity analysis displayed 
77.9% of the ICER distribution in the dominant quadrant. Acceptability curve showed 
that daptomycin was q88.6% cost-effective compared to vancomycin at all ICER
ranges. CONCLUSIONS: Daptomycin was cost-effective compared to vancomycin
due to decreased total direct cost and reduction in inpatient stay. As a result, the pro-
portion of ICER in the probabilistic sensitivity analysis favored daptomycin 77.9%
which was reﬂ ected in the acceptability curve.
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OBJECTIVES: The ritonavir-boosted protease inhibitor (PI/r) darunavir (darunavir/r)
800/100 mg QD has recently been licensed in the US for use in treatment-naïve 
HIV-infected adults. The objective of this study was to compare the cost and efﬁ cacy 
of darunavir/r-based triple therapy with other combination therapies using PI/rs 
currently licensed for this patient population in the US. METHODS: Virologic efﬁ cacy 
was measured by the percentage of individuals with plasma HIV RNA  50 copies/mL 
(the current goal of antiretroviral therapy) at 48 weeks, based on a systematic review
of clinical trials of PI/r-based regimens in treatment-naïve populations. One-year 
antiretroviral therapy costs were calculated in 2008 US dollars. The base-case analysis 
considered PI/rs with a tenofovir-based backbone regimen; an abacavir-based back-
bone was considered in scenario analysis. RESULTS: The base-case analysis showed
that darunavir/r was the most efﬁ cacious PI/r, with an incremental cost-efﬁ cacy 
ratio (ICER) of $31,524 per additional individual with virologic response, when 
compared with fosamprenavir/r, the only other point on the efﬁ ciency frontier of 
PI/r-based initial therapy. All other PI/rs were less efﬁ cacious and more costly than 
darunavir/r or fosamprenavir/r, including the two most commonly prescribed: atazana-
vir/r and lopinavir/r. Before the introduction of darunavir/r, atazanavir/r was most
efﬁ cacious but with a higher ICER of $46,612 compared with fosamprenavir/r.
Darunavir/r has an average cost of $25,059 per individual with virologic response, 
compared with $25,880 and $26,526 for atazanavir/r and lopinavir/r, respectively. 
Given a ﬁ xed budget of $10 million, darunavir/r successfully treats 399 individuals,
compared with 386 and 377 for atazanavir/r and lopinavir/r, respectively. Similar
results were obtained in scenario analysis using an abacavir-based backbone. CON-
CLUSIONS: Darunavir/r 800/100 mg QD has a lower cost per individual with viro-
logic response after 48 weeks than the 2 most commonly prescribed PI/rs in 
treatment-naïve, HIV-infected adults and provides more beneﬁ t per additional cost 
than other currently available PI/rs.
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OBJECTIVES: To assess the cost-effectiveness of Truvada versus Combivir and Kivexa
in the treatment of antiretroviral naïve HIV-1 infected patients in Mexico. METHODS:
A Markov model was developed to assess the incremental cost effectiveness of Truvada
vs Combivir and Kivexa. Clinical data was derived from published clinical trials (Study 
903 and CNA30024) and other secondary sources to create a model of disease pro-
gression and treatment patterns. Both health care and treatment costs were considered.
The analysis was performed from the Mexican Health Care System perspective; costs 
were reported in 2008 US dollar. Costs and health outcomes were discounted at 5%.
A second-order probabilistic Monte Carlo sensitivity analysis was conducted to assess 
the effects of parameter uncertainty on the study ﬁ ndings. RESULTS: The model 
projects an accumulated discounted cost to the Mexican health care system per patient 
receiving the Truvada regimen of US$28,776 compared to US$24,605 for the Kivexa
regimen and US$22,999 for the Combivir regimen. The accumulated discounted effect
is 5.85 QALYs per patient receiving Truvada compared to 4.89 QALYs for Kivexa
and 4.81 QALYs for Combivir. This results in an incremental cost for Truvada and
Kivexa vs. Combivir of US$5,805 per QALY and US$ 19,436 per QALY respectively. 
Considering a willingness to pay (WTP) threshold of US$10,000 per QALY there is a
90% probability that treatment with Truvada is cost-effective relative to Combivir
CONCLUSIONS: Results from these analyses suggest that in the Mexican setting, use
of Truvada in place of standard Combivir and Kivexa for treatment of HIV is likely
to be cost effective. These conclusions are supported by conservative assumptions and
sensitivity analyses.
PIN15
COMPARING COST-EFFECTIVENESS OF THE THREE- VERSUS TWO-DOSE
VACCINATION PROTOCOL AGAINST HEPATITIS B IN ADOLESCENTS
Hajarizadeh B1, Rashidian A1, Haghdoost AA2, Alavian SM3
1Tehran University of Medical Sciences, Tehran, Tehran, Iran, 2Kerman University of Medical 
Sciences, Kerman, Kerman, Iran, 3Baqyatallah Research Center for Gastroenterology and Liver 
Diseases, Tehran, Tehran, Iran
OBJECTIVES: A three-dose regimen is the usual protocol for hepatitis-B vaccination. 
An alternate two-dose vaccination schedule has been recently approved for adoles-
cents. This study was conducted to compare cost-effectiveness of three- versus two-
dose hepatitis-B vaccination regimen in adolescents. METHODS: We applied health 
care provider perspectivein this study. To measure vaccination coverage and costs, we 
retrieved the data of hepatitis-B mass vaccination campaign run in 2007 covering 
1989-born adolescents in Iran. Vaccines immunogenicity were derived from literature.
The cost variables considered included recurrent costs, personnel costs, publicity costs, 
transportation costs, and overhead costs. The required data to estimate recurrent, 
national-level supervision, and publicity costs were provided from existing data and 
interview with experts. To estimate vaccine administration, provincial supervision, and
outreach costs, the data were provided from some provinces and projected to the
country. We used WHO recommended proportions to estimate transportation and 
overhead costs. RESULTS: Total cost for a three-dose campaign was estimated as $2.3
per-dose-administered. The same cost for two-dose campaign would be $2.1 per-dose-
administered. Total cost of a three-dose campaign, in the best scenario was $7.1 per-
person-seroprotected and would be $5.5-$9.4 in alternative scenarios according to 
sensitivity analysis. The same cost for a two-dose campaign, in the best scenario was
$4.5 per-person-seroprotected and would be $3.6-$8.7 in alternative scenarios. To 
immunize one more person in a 3-dose protocol compared to a 2-dose protocol, $58.6 
would be spent by health system. This cost would be $9.6-$155.3 in various scenarios. 
In addition, in some scenarios two-dose protocol might have deﬁ nite priority to three-
dose protocol because of both higher effectiveness and lower cost. CONCLUSIONS:
Running a two-dose protocol HBV vaccination campaign in adolescents instead of 
current three-dose protocol campaign is more cost-effective. Conducting an analysis 
with societal perspective which includes vaccinee costs, two-dose protocol will be more 
advantageous.
PIN16
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OBJECTIVES: This study aims to conduct cost-effectiveness analysis of posaconazole 
(POS) compared with standard azole therapy including ﬂ uconazole (FLU) or itracon-
azole (ITR) for prophylaxis of invasive fungal infection (IFI) with netropenia in South 
Korea. METHODS: A decision tree was used to estimate the proportion of the surviv-
ing patients cohort during the 100-day period following initiation of prophylaxis. The
surviving patients in the decision tree were extrapolated to a lifetime horizon using
Markov model to estimate the incremental cost per life-year gained. Effectiveness 
parameters used in the decision tree were obtained from clinical trial. And IFI treat-
ment costs were estimated from hospital survey. The price of POS was proposed by 
the manufacturing company and calculated based on the average KRW-Euro exchange
rate of 2008. Deterministic one-way and probabilistic sensitivity analyses (PSA) were 
conducted, as well. RESULTS: Base-case analysis showed that POS resulted in a gain
of 0.092 life years (2.417 vs. 2.324) with KRW 1,457,512 of additional costs (KRW 
5,827,956 vs. 4,370,443) per patient relative to FLU or ITR. While the drug cost of 
POS was higher than that of FLU/ITR, expected IFI treatment costs were lower in
patients with POS than in patients with FLU/ITR. The incremental cost-effectiveness 
ratio was KRW 15,798,087 (€9,995) per life-year gained. PSA revealed that POS was 
cost-effective with a 50% probability at about KRW 22,000,000 (€14,000). CON-
CLUSIONS: The results of cost-effectiveness analysis showed that POS is potentially 
beneﬁ cial in IFI prophylaxis among patients with neutropenia in South Korea.
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BACKGROUND: Human papillomavirus (HPV), a precursor for cervical cancer, is 
the most common sexually transmitted infection in the United States. A quadrivalent 
vaccine (Gardasil), which was approved by the US FDA in June 2006, targets HPV 
16 and 18, which cause 70% cervical cancer, and HPV 6 and 11, which cause genital 
warts. OBJECTIVES: To evaluate the cost-effectiveness of HPV vaccine compared to 
the current screening program. The result expressed by quality-adjusted life-years
(QALYs), and incremental cost-effectiveness ratios (ICER). METHODS: A backward 
induction model was used to estimate the results. A cohort of female aged 12 to 70 
was projected. Girls are vaccinated at age 12, assuming that this vaccine is life-long 
protective, 85% efﬁ cacy, women complete 3 shots and assuming a 3% discount rate.
Model parameters were taken from published literature. Costs and QALYs were cal-
culated in 5-years intervals. One-way sensitivity analyses were conducted on critical 
or uncertain model parameters. RESULTS: HPV vaccines had both higher total costs 
($48,342) and higher QALYs (3.07 days) than girls receiving screening tests. The 
vaccine cost-effectiveness ratio was $15,749 per quality-adjusted life-year (QALY) 
